Douglas Johnson

September 13, 2018

Study tracks incidence, timing of immunotherapy-related deaths

Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

By Tom Wilemon
April 12, 2018

Entertainers’ support strengthens VICC melanoma research efforts

Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.

By VUMC News and Communications
March 12, 2018

Cancer immunotherapy drugs linked with more serious heart effects

Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

By VUMC News and Communications
November 3, 2016

Study details rare heart risk of certain cancer therapies

By VUMC News and Communications
May 26, 2016

Precision medicine already changing cancer treatment strategies

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.

By VUMC News and Communications
March 3, 2016

Melanoma response to immune therapy

Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

By Leigh MacMillan
October 29, 2015

Investigators find clues to melanoma treatment resistance

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.
By VUMC News and Communications
March 12, 2015

Gene mutations may predict melanoma response to immunotherapies

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.
By VUMC News and Communications
1 2